Study details
Enrolling now
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
National Heart, Lung, and Blood Institute (NHLBI)
NCT IDNCT06313398ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
100
Study length
about 5.1 years
Ages
18–100
Locations
1 site in MD
What this study is about
This trial is testing how long red blood cells survive in people with sickle cell disease (SCD) and other hemoglobinopathies. The researchers will use biotin labeling to track the lifespan of these cells, comparing them to those who have had a bone marrow transplant. This information could help improve treatments for these conditions.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Biotin-labeled red blood cells
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
ALIMENTARY TRACT AND METABOLISM
Drug routes
oral (Oral Tablet)